mTOR in GLP‐1 analog apoptosis protection

E-ISSN： 1753-0407|7|2|231-239

ISSN： 1753-0393

Source： JOURNAL OF DIABETES, Vol.7, Iss.2, 2015-03, pp. : 231-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTOR

By Marin Philippe Meffre Julie Bockaert Joël

Médecine/sciences, Vol. 29, Iss. 1, 2013-01 ,pp. : 28-30

Edp Sciences

Access to resources Recommend Favorite

The mTOR Pathway in Breast Cancer

By Hynes Nancy Boulay Anne

Journal of Mammary Gland Biology and Neoplasia, Vol. 11, Iss. 1, 2006-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite

Liraglutide: a human GLP-1 analog for Type 2 diabetes

By Vilsbøøll Tina

Therapy, Vol. 6, Iss. 2, 2009-03 ,pp. : 199-207

Future Medicine

Access to resources Recommend Favorite

Alterations of the mTOR pathway in hepatic angiomyolipoma with emphasis on the epithelioid variant and loss of heterogeneity of TSC1/TSC2

HISTOPATHOLOGY, Vol. 66, Iss. 5, 2015-04 ,pp. : 695-705

John Wiley & Sons Inc

Access to resources Recommend Favorite

The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 455-458

John Wiley & Sons Inc

Access to resources Recommend Favorite